Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

al patients will be enrolled in this Phase I study which is due to be completed in December 2007.

Phase 1 preliminary trial data and the ASCO Poster Presentation can be found on the CytImmune website, www.cytimmune.com <http://www.cytimmune.com/> . All data has been released according to ASCO's Abstract Policy. The American Society of Clinical Oncology Annual Meeting is considered the premier educational and scientific event in the oncology community. In 2006, more than 29,000 attendees from around the world participated in the 42nd ASCO annual meeting in Atlanta, Georgia.

ABOUT CYTIMMUNE

CytImmune Sciences is a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies harnessing the unique properties of gold nanoparticles, known anti-cancer agents and biology of tumors. The platform technology allows for the targeted delivery of anti-caner therapies while avoiding update by healthy organs and tissues leading to improved efficacy, safety and patient outcomes. CytImmune hopes to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits.


'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Post Your Comments:
(Date:11/6/2009)...IS, Nov. 6 Recession in ...press sales for Allied Healthcare Products in the ... 30, 2009. ,, Sales declines pushed Allied into...rter was about $745,000, or negative 9 cents per s... about $208,000, or 3 cents per share. ,, Sale...
(Date:11/6/2009)..., Calif., Nov. 6 Kaiser Foundation...FHP/H), and their subsidiaries reported today a co...r the quarter ended September 30, 2009, compared t... Operating income in the third quarter was $336 mi...er of last year. Net non-operating income was $233...
(Date:11/6/2009)...TON, Nov. 6 America,s S...orking group of mid-market and smaller innovator p...about H.R. 3962, the "Affordable Health Care for A...ursday. These smaller companies fear that the cum...2 will hinder their efforts to bring new medicines...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2ChemImage Works to Improve Existing Methods of Imaging Untreated Fingerprints on Paper Substrates 12460 1ChemImage Works to Improve Existing Methods of Imaging Untreated Fingerprints on Paper Substrates 12460 2Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 1Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 2Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 3Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 4Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 1Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 2Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 3
... TURKU, Finland, May 28 BioCis Pharma Ltd., a,pri...quarters in Turku,Finland, has started Phase I cli...lation solution, a novel anti-cancer drug for urin...chanism of action discovered and developed by,BioC... and proliferation,locally. , The open-label, ...
... AMSTERDAM, May 28 Amsterdam Molecular,Therapeuti... gene therapy,announced today that the European Me... to AMT,s gene therapy product AMT-021 for the tre... Orphan Drug Designation for AIP entitles AMT to ...rketing approval for AMT-021 if this,product candi...
Other Medicine Technology:BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 3
(Date:11/8/2009)... won," said Dr. Charmaine Yoest. ,, WASHINGTON...40-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemp...andates and funding in HR 3962 passed on the House...sident and CEO Dr. Charmaine Yoest said, "The pass...e Americans across this country who have flooded C...
(Date:11/8/2009)...Secure the Stability of Medicare ,, HOUSTON, N...table to: J. James Rohack, M.D., President, Americ...newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ,...eform bill, which will help improve the health sys...t passage of H.R. 3961 to secure the stability of ...
(Date:11/8/2009)...e Reform Bill ,, Critical legislation would s...cans ,, BALTIMORE, Nov. 7 /PRNewswire-USNewswi...of Representatives passed critical health care ref... seniors and end discrimination by insurance compa...rdable health coverage. ,, The Affordable Healt...
(Date:11/7/2009)...-- The American Medical Association (AMA) today aw... and Community Service to Manus C. Kraff, M.D., an...nizes physicians who have gone above and beyond th...ng public service contribution to their local comm...he opening session of the 2009 Interim Meeting of ...
(Date:11/7/2009)...- Members of the AMA are trying a last-minute tact... the AMA,s support of HR 3962. ,, "We want to ...ir PATIENTS, not the leadership of the AMA," said ...tion of American Physicians and Surgeons, and Take...s. ,, "If the AMA leadership ignores the publi...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
... chronic disease care, study finds , , TUE...factor driving soaring rates of chronic disease in...ically ill than their European counterparts, a new...o $150 billion in health-care spending in the Unit...
... Inc. (OTCBB: MITD - News), has signed an agreemen...ducts to stop the spread of infectious diseases. ...ientific Advisor and Director of the Biodefense an...ill oversee the project. , This is a significan...
...st significant genetic finding in premenstrual dys...D is a very severe form of the more commonly known..., affects 5-8% of women, and is associated with se...ity of life is seriously impacted. Previously, re...
... Diagnostics, Inc. and,Otsuka America Pharmaceutic...a merger between the two companies. The merger for...cs Group of Otsuka America Pharmaceutical,Inc. OA...ired by OAI in 2001. Both are part of the Otsuka P...
...ivision of,Filtrona plc, developer of fiber-based ...uid handling components, celebrated the completion...hina with a Grand Opening,celebration. (Logo: ht...d an expanded analytical laboratory to support the...
...all/-- ReBuilder Medical,Technologies, Inc. (Pink ...easing demand for its products it has had to incre...n the past three weeks alone. (Logo: http://www....and our SilverCure(TM) products over five,years, a...
Other Medicine News:Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger 2Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 3
... the functional management of grade I, II, and III...ed aircell, the brace provides focused, pneumatic ...upporting the arm and shoulder. A detachable sling...al arm support and helps to unload the waist strap...
Humeral Stabilizing System (HSS)
Humerus Fracture Brace
Functional Arm Brace
Medicine Products: